Loading...
High-performance liquid chromatographic assay for the novel antitumor drug, bryostatin-1, incorporating a serum extraction technique.
Khan, Parveen McGown, Alan T Dawson, Martin J Prendiville, Joseph A Pettit, G R Crowther, Derek
Khan, Parveen
McGown, Alan T
Dawson, Martin J
Prendiville, Joseph A
Pettit, G R
Crowther, Derek
Citations
Altmetric:
Abstract
An HPLC assay incorporating a solid-phase extraction technique has been devised for bryostatin-1. Quantitation of bryostatin was found to be linear over the concentration range 0.012-25 microg/ml (0.2-25 ng on column) and was found to have a limit of detection of 0.2 ng on column, with a correlation coefficient of 0.9999. Following extraction of bryostatin over a range of concentrations from horse serum (0.012-25 microg/ml) and human serum (0.01-0.32 microg/ml) using a 100-mg C18 solid-phase extraction cartridge, extraction efficiencies consistently greater than 90% were obtained for extraction from horse serum and varied between 57 and 85% from human serum. However, on extending this work to blood samples from patients undergoing therapy with bryostatin-1, the drug was not detectable even at the maximum dose given, demonstrating the rapid loss of this agent from peripheral circulation.
Description
Date
1998-05-08
Publisher
Keywords
Type
Article
Citation
High-performance liquid chromatographic assay for the novel antitumor drug, bryostatin-1, incorporating a serum extraction technique. 1998, 709 (1):113-7 J. Chromatogr. B Biomed. Sci. Appl.